List of Excipients in Branded Drug AVALIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sanofi-Aventis US LLC	AVALIDE	irbesartan and hydrochlorothiazide	0024-5855	CARNAUBA WAX
Sanofi-Aventis US LLC	AVALIDE	irbesartan and hydrochlorothiazide	0024-5855	CELLULOSE, MICROCRYSTALLINE
Sanofi-Aventis US LLC	AVALIDE	irbesartan and hydrochlorothiazide	0024-5855	CROSCARMELLOSE SODIUM

AVALIDE Excipient Strategy and Commercial Opportunities: Formulation, Generic Entry, and Market Analysis

Last updated: August 24, 2026

Avalide is the fixed-dose combination of irbesartan and hydrochlorothiazide used for hypertension. Its active ingredients are off-patent small molecules, and U.S. commercial opportunity is concentrated in generic supply, differentiated oral-tablet formulations, contract manufacturing, and emerging-market fixed-dose combinations. Excipient selection can improve manufacturability, dissolution consistency, tablet robustness, stability, and suitability for patients with lactose or swallowing concerns.

What is Avalide and how is it formulated?

Avalide contains the angiotensin II receptor blocker irbesartan and the thiazide diuretic hydrochlorothiazide. The original product was approved by the FDA as an immediate-release oral tablet in multiple strengths, including 150 mg/12.5 mg, 300 mg/12.5 mg, and 300 mg/25 mg presentations.[1]

Attribute	Avalide
Active ingredients	Irbesartan and hydrochlorothiazide
Dosage form	Immediate-release tablet
Therapeutic class	Antihypertensive fixed-dose combination
Primary indication	Hypertension
Original manufacturer	Sanofi, historically marketed through the Bristol-Myers Squibb/Sanofi relationship
U.S. regulatory status	Approved drug product; generic versions are available
Biosimilar relevance	None; Avalide is a small-molecule product
Main commercial substitutes	Generic irbesartan/hydrochlorothiazide, separate irbesartan and hydrochlorothiazide tablets, other ARB/thiazide combinations

The Avalide formulation uses conventional tablet excipients rather than a modified-release or drug-delivery platform. Public product information identifies common formulation components such as lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, colloidal silicon dioxide, magnesium stearate, titanium dioxide, polyethylene glycol, and colorants, depending on strength and presentation.[1,2]

The formulation strategy is consistent with a conventional wet- or dry-granulated immediate-release tablet:

1. Fillers and diluents provide tablet mass and compressibility.
2. Superdisintegrants promote rapid tablet breakup.
3. Glidants improve powder flow.
4. Lubricants reduce sticking and ejection force.
5. Film-coating materials improve appearance, handling, swallowability, and protection from environmental exposure.

What excipients are used in Avalide tablets?

Avalide’s excipient profile is commercially important because generic manufacturers can use different inactive ingredients while demonstrating pharmaceutical equivalence and bioequivalence.

Core excipient functions

Excipient category	Typical Avalide-related material	Commercial function
Diluent	Lactose monohydrate, microcrystalline cellulose	Adds bulk and supports compression
Disintegrant	Croscarmellose sodium	Promotes tablet breakup and drug release
Binder or film former	Hypromellose	Supports coating and tablet integrity
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate	Reduces friction during compression and ejection
Opacifier	Titanium dioxide	Improves coating opacity and appearance
Plasticizer or coating aid	Polyethylene glycol	Improves film flexibility and coating performance
Colorant	Iron oxides or other approved colorants, depending on product	Supports strength identification and branding

The formulation has two active pharmaceutical ingredients with different physicochemical properties. Irbesartan is a poorly water-soluble compound, while hydrochlorothiazide has limited solubility and can present dose-uniformity and dissolution challenges. A generic manufacturer therefore must control particle-size distribution, blending, segregation, granulation behavior, compression force, and dissolution performance.

Excipient substitution is possible, but changes may affect:

• dissolution profiles;
• content uniformity;
• tablet hardness and friability;
• disintegration time;
• moisture sensitivity;
• coating adhesion;
• stability;
• gastrointestinal tolerability;
• labeling obligations for allergens or excipient sensitivities.

How should an excipient strategy for Avalide be designed?

A strong excipient strategy should focus on performance, supply security, regulatory simplicity, and differentiation rather than attempting to replicate the branded tablet exactly.

Strategy 1: Standard lactose-based immediate-release platform

A lactose and microcrystalline cellulose system is suitable for a low-cost generic product where manufacturing infrastructure already supports conventional compression or granulation.

Advantages include:

• broad supplier availability;
• established compendial specifications;
• low cost;
• compatibility with standard tablet equipment;
• straightforward regulatory justification.

The main risks are lactose intolerance concerns, supplier variability, moisture effects, and possible interaction with formulation water activity. Lactose intolerance usually does not preclude use of small pharmaceutical quantities, but a lactose-free presentation can support institutional procurement and patient-preference positioning.

Strategy 2: Lactose-free formulation

A lactose-free product can replace lactose with materials such as mannitol, dibasic calcium phosphate, starch derivatives, or additional microcrystalline cellulose. The choice depends on tablet size, compressibility, dissolution, and stability targets.

Potential commercial advantages include:

• access to customers with lactose-free procurement policies;
• differentiation in markets with strong excipient labeling requirements;
• suitability for patients who prefer to avoid lactose;
• simplified positioning for selected hospital or specialty-pharmacy channels.

The main technical trade-off is that calcium phosphate, mannitol, and cellulose-based systems produce different compaction, disintegration, and moisture profiles. The substitution must be evaluated across all three Avalide strengths rather than extrapolated from a single dose.

Strategy 3: Direct-compression formulation

Direct compression can reduce manufacturing steps and operating costs. It requires excipients with consistent flow, density, and compactability. Microcrystalline cellulose, spray-dried lactose, mannitol, and co-processed excipients can support this approach.

Direct compression is attractive when:

• active ingredients have suitable flow and content-uniformity characteristics;
• the formulation has adequate tablet strength at low compression force;
• segregation is controlled;
• the product can meet dissolution specifications without granulation.

The risk is that the two active ingredients may segregate because of differences in particle size, density, or loading. Irbesartan represents the higher mass fraction in the combination, but hydrochlorothiazide still requires reliable low-dose distribution. Blend uniformity and in-process controls are central development issues.

Strategy 4: Granulation-based formulation

Wet or dry granulation can improve blend uniformity and compressibility. Dry granulation may be preferable where moisture sensitivity or process simplicity is a concern. Wet granulation can improve powder handling but adds drying, solvent, and scale-up requirements.

A granulation process may be commercially justified when:

• direct compression produces unacceptable weight variation;
• the tablet is too large;
• the formulation has poor flow;
• dissolution needs tighter control;
• manufacturing equipment is already configured for granulation.

The cost penalty is higher processing complexity and potentially greater batch-cycle time.

Strategy 5: Co-processed excipient platform

Co-processed excipients can combine filler, binder, and disintegrant functions. This can reduce formulation complexity and improve manufacturing consistency. The opportunity is strongest for contract manufacturers seeking a repeatable platform across multiple ARB combinations.

The limitation is supplier dependence. A proprietary co-processed excipient can create cost and continuity risk if there is only one qualified source. A dual-source strategy is preferable for a high-volume generic.

What formulation patents protect Avalide?

Avalide’s principal U.S. commercial protection has expired. Irbesartan and hydrochlorothiazide are established small molecules, and the product is subject to generic competition. The original combination and product-related patent landscape is historical rather than an active barrier to ordinary U.S. generic entry.[3]

Protection category	Avalide position
Active-ingredient composition patents	Expired or no longer commercially blocking in the U.S.
Fixed-dose combination patents	Historical protection; no longer a meaningful barrier to routine generic entry
Formulation patents	Any historical claims must be reviewed by jurisdiction and claim scope; no broad current barrier is apparent for conventional immediate-release tablets
Method-of-use patents	Hypertension treatment claims are generally old and commercially weak against generic entry
Regulatory exclusivity	Original exclusivity periods have expired
Orange Book relevance	Current Orange Book listings must be checked for the specific reference-listed product and jurisdictional status

A generic applicant does not normally need to copy every inactive ingredient in Avalide. Under the abbreviated new drug application pathway, the applicant must demonstrate pharmaceutical equivalence and bioequivalence and meet applicable quality and labeling requirements.[4]

A formulation patent could still matter if it claims a narrow excipient ratio, particle-size distribution, coating system, dissolution profile, or manufacturing process. Such a patent would need to be assessed claim by claim. Broad protection for a conventional irbesartan/hydrochlorothiazide tablet is unlikely to provide durable exclusivity because the product class is mature and genericized.

What is the Orange Book status of Avalide?

The FDA Orange Book identifies approved drug products and relevant patent or exclusivity information for listed reference products.[3] Avalide’s original regulatory exclusivity and core patent protection are no longer the primary commercial issue. The current competitive question is whether any particular listed patent, use code, or later-added formulation claim remains relevant to an ANDA applicant.

For a current diligence review, the relevant checks are:

• whether Avalide remains listed as the reference product;
• whether the specific strength is still marketed;
• whether any patent is listed against the relevant strength;
• whether the patent has expired, been delisted, or been declared invalid;
• whether a generic applicant filed a Paragraph IV certification;
• whether litigation triggered a 30-month stay;
• whether settlements restricted launch timing.

The commercial significance of Paragraph IV risk is now limited compared with the product’s launch period because multiple generic manufacturers have already entered the market. A new entrant would generally face price competition rather than a single-originator patent barrier.

When did Avalide lose exclusivity?

Avalide lost meaningful U.S. exclusivity after the expiration of the relevant irbesartan and combination-product protections. Generic versions became available, and the product moved from an originator-protected market to a multi-supplier market.

The practical timeline is:

Period	Commercial status
1990s	Original Avalide development and FDA approval
2000s	Originator sales under patent and regulatory protection
Around the early 2010s	Generic-entry period following expiration of key protections
Current market	Generic-dominated, price-sensitive market

The exact entry date varies by strength, applicant, and regulatory approval. Generic launch timing should be confirmed through FDA approval records, ANDA approval histories, and the Orange Book rather than inferred from the original brand approval date.

Which companies challenge or compete with Avalide?

Competition comes primarily from generic manufacturers rather than biosimilar developers. Potential suppliers include large multinational generic companies, U.S. specialty-generic manufacturers, and regional manufacturers that produce irbesartan/hydrochlorothiazide tablets under local approvals.

The competitive set includes:

• generic irbesartan/hydrochlorothiazide tablets;
• separate irbesartan and hydrochlorothiazide products;
• losartan/hydrochlorothiazide;
• valsartan/hydrochlorothiazide;
• olmesartan/hydrochlorothiazide;
• candesartan/hydrochlorothiazide;
• telmisartan/hydrochlorothiazide.

A fixed-dose combination competes on pill burden, adherence, price, formulary status, and physician familiarity. Separate-component therapy competes on dose flexibility and titration control.

What commercial opportunities exist for Avalide excipients?

The strongest opportunities are in generic manufacturing and differentiated formulation platforms.

Generic private-label and contract manufacturing

A manufacturer can supply multiple customers using a validated immediate-release platform with strength-specific tooling and common excipient systems. The opportunity is strongest where the manufacturer has:

• low-cost tablet capacity;
• robust analytical methods;
• established stability data;
• access to approved excipient suppliers;
• experience with ANDA or national generic submissions.

A dual-source excipient program can reduce supply interruption risk, especially for microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and coating polymers.

Lactose-free and patient-preference products

Lactose-free irbesartan/hydrochlorothiazide tablets can create a modest differentiation opportunity. The value is more likely to arise from formulary or procurement requirements than from premium pricing, because hypertension medicines are highly price sensitive.

Smaller tablet and swallowability designs

Tablet size is relevant for older patients, who represent a major hypertension-treatment population. A formulation that maintains dose uniformity and dissolution in a smaller tablet may improve patient acceptability. Opportunities include:

• higher-density excipient systems;
• optimized granulation;
• film coatings with lower weight gain;
• debossing and color coding for strength recognition.

Any reduction in tablet size must be balanced against compression defects, capping, friability, and dissolution changes.

Supply-chain differentiation

Excipient availability can become a commercial advantage when competitors depend on a single supplier or a narrow grade specification. A manufacturer can qualify multiple sources and design the formulation around excipients with:

• compendial status;
• stable global supply;
• consistent particle-size distribution;
• validated functionality;
• low regional regulatory risk.

Emerging-market fixed-dose combinations

Markets with high hypertension prevalence and growing generic penetration may offer more volume opportunity than the U.S. The regulatory strategy will vary by country, and local requirements may include comparative dissolution, local bioequivalence, stability under climatic conditions, and different excipient restrictions.

Geographic opportunity is strongest where:

• fixed-dose combinations are included in treatment guidelines;
• public procurement favors low-cost combination tablets;
• local manufacturing receives regulatory or pricing advantages;
• branded-generics retain meaningful market share.

What manufacturing and intellectual-property barriers remain?

The main barriers are technical and commercial rather than patent-based.

Manufacturing barriers

• Maintaining uniform distribution of hydrochlorothiazide.
• Controlling irbesartan dissolution despite low aqueous solubility.
• Managing powder segregation during transfer and compression.
• Preventing sticking, picking, capping, and lamination.
• Controlling magnesium stearate over-lubrication.
• Demonstrating stability across multiple climate zones.
• Requalifying the product after major excipient or supplier changes.

Intellectual-property barriers

Potential risks include narrow formulation patents, process patents, trademark restrictions, and jurisdiction-specific data exclusivity. These risks are more relevant outside the mature U.S. market, where local patent registers and national regulatory rules may differ.

A company should not assume that U.S. patent expiry establishes freedom to operate globally. India, Brazil, China, Canada, Europe, and other markets may have different patent histories, supplementary protection mechanisms, regulatory pathways, or local litigation records.

How strong is the Avalide patent estate?

The patent estate is commercially weak for conventional U.S. generic entry because the product is mature, the active ingredients are established, and generic competition exists. The remaining value lies in execution:

• reliable bioequivalence;
• cost-effective excipient selection;
• manufacturing yield;
• supply continuity;
• regulatory coverage;
• institutional contracting;
• geographic expansion.

A new patent strategy would have greater value if it addressed a technically meaningful improvement, such as a stable low-dose blend, a smaller tablet, a lactose-free composition, an improved dissolution profile, or a manufacturing process that materially reduces cost. A purely cosmetic excipient change would have limited defensibility.

What generic launch scenarios exist for Avalide?

Launch scenario	Commercial profile	Main risk
Lowest-cost standard generic	High volume, low margin	Rapid price erosion
Authorized or private-label supply	Contracted volume and distribution	Customer concentration
Lactose-free product	Moderate differentiation	Limited premium potential
Smaller-tablet formulation	Patient and prescriber differentiation	Development and bioequivalence risk
Emerging-market branded generic	Higher margin in selected markets	Local regulatory and pricing risk
Dual-source excipient platform	Supply-chain advantage	Qualification cost
Separate-component portfolio	Broad dose flexibility	Higher pill burden

Revenue exposure for the original Avalide brand is likely limited relative to its protected period because generic substitution has reduced branded volume. Public disclosures do not consistently report Avalide revenue as a standalone current product line. Commercial assessment should therefore focus on market share, unit volume, tender awards, and net price by country rather than historical brand sales alone.

Key Takeaways

• Avalide is an immediate-release irbesartan/hydrochlorothiazide tablet with expired core U.S. exclusivity.
• Its excipient system is conventional and can be redesigned without copying the branded inactive-ingredient profile.
• Lactose-free, smaller-tablet, direct-compression, and supply-secure formulations offer the clearest differentiation opportunities.
• Generic entry risk is high because the product is mature and biosimilar competition is irrelevant.
• The principal barriers are bioequivalence, dissolution control, blend uniformity, manufacturing economics, and regional regulatory requirements.
• U.S. commercial value is concentrated in low-cost generic supply, private-label manufacturing, and institutional contracting.
• Global opportunities depend on country-specific patent, regulatory, procurement, and pricing conditions.
• A defensible new patent position would require a measurable technical advantage, not a routine excipient substitution.

FAQs About Avalide Excipient and Commercial Strategy

Can a generic Avalide tablet use different excipients?

Yes. A generic applicant can use different inactive ingredients if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, stability, and labeling requirements.

Is Avalide a biologic that can face biosimilar competition?

No. Avalide contains small-molecule active ingredients. Its competitive risk comes from generic tablets and alternative antihypertensive combinations, not biosimilars.

Is a lactose-free Avalide formulation commercially attractive?

It can provide modest differentiation for institutional procurement and patient-preference segments. It is unlikely to support a large price premium in heavily genericized hypertension markets.

Which excipient is most important for Avalide dissolution?

No single excipient determines performance. Disintegrant level, active-particle size, granulation, compression force, lubricant concentration, and coating behavior jointly control dissolution.

Can a smaller Avalide tablet be patented?

Possibly, but only if the claims provide a novel and non-obvious technical solution, such as a defined composition or process that produces a measurable performance advantage. Routine substitution of one diluent for another would generally provide weak patent protection.

References

1. U.S. Food and Drug Administration. (n.d.). Avalide (irbesartan and hydrochlorothiazide) prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Avalide, irbesartan and hydrochlorothiazide tablet.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an abbreviated new drug application.